Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

12articles mentioning drugs

14drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: Bictegravir ×

Bictegravir

This drug is selected. Its supporting articles are shown below.

Bictegravir12

Articles mentioning Bictegravir

12 articles · page 1 of 1

P20 B/F/TAF vs DTG: similar durability, different reasons for discontinuation. results of a real-life study

sextrans · abstract · 2026-05-20 · 3 matching annotations

94.4%

Dolutegravir bictegravir darunavir abacavir atazanavir rilpivirine 3TC lamivudine emtricitabine DTG+1 more

…ain characteristics of 2359 PWH enrolled in the Bictegravir and Dolutegravir SCOLTA cohortsAbstract P20 Table 2Reasons for 568 discontinuati…

Monkeypox-associated keratitis and glabellar lesion mimicking a third eye

bmjcr · abstract · 2026-06-19 · 1 matching annotations

92.3%

bictegravir emtricitabine tenofovir neurosyphilis HIV/AIDS

…viral load 8,000 copies/mL, with self-reported non-adherence to bictegravir/emtricitabine/tenofovir (Bikatrvy)), neurosyphilis with prior o…

OC36 Durability of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir-based single tablet regimens in a large cohort of experienced PWH: the BIC-LASTING study

sextrans · abstract · 2026-06-05 · 1 matching annotations

91.1%

dolutegravir bictegravir emtricitabine DTG tenofovir alafenamide abacavir 3TC rilpivirine DTG-STR lamivudine

…ctegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) vs. dolutegravir (DTG)-based single tablet regimens (STR) on treatment failure-r…

P148 Changes in body weight and metabolic parameters in people living with HIV starting an initial regimen with tenofovir disoproxil fumarate/lamivudine/doravirine or tenofovir alafenamide emtricitabine/ bictegravir or lamivudine/dolutegravir (WEINF Study)

sextrans · abstract · 2026-06-05 · 1 matching annotations

89.4%

DOL/3TC tenofovir alafenamide bictegravir tenofovir disoproxil fumarate emtricitabine BIC/F/TAF DOR/3TC lamivudine

… comparable in subjects treated with DOR/3TC/TDF, BIC/F/TAF, or DOL/3TC.Conclusions In our study, initial antiretroviral regimen with D…

P97 Hepatic health restoration and immune optimization in ART-naïve PWH starting BIC/FTC/TAF: a 96-week multicenter analysis of FIB-4 dynamics and CD4/CD8 ratio abstract

sextrans · abstract · 2026-06-05 · 1 matching annotations

85.8%

bictegravir SHINE SHIC ART

…ine was observed, consistent with the known pharmacodynamics of bictegravir on tubular secretion.Conclusions In this 96-week real-world ana…

SC33 Long-term durability of BIC/FTC/TAF in virologically suppressed PWH in a real-world setting

sextrans · abstract · 2026-06-05 · 1 matching annotations

91.0%

tenofovir alafenamide Bictegravir emtricitabine PWH HIV-RNA HIV

…rapy in people living with HIV (PWH). Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) showed efficacy and tolerability in randomized tr…

SC34 12 months effectiveness and safety of switching to BIC/FTC/TAF in virologically suppressed people with HIV on any ARV-regimens including NNRTIs: a retrospective analysis (ESSENTIAL study)

sextrans · abstract · 2026-06-05 · 1 matching annotations

93.7%

tenofovir alafenamide emtricitabine bictegravir Gilead Sciences PWH ASST Fatebenefratelli Sacco HIV HIV-RNA

…ectiveness and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), including switches from rilpivirine-based regime…

OC48 Comparison between next-generation sequencing and historical genotypic resistance testing at virological failure in ART-experienced individuals: data from the ARCA cohort and the Italian NGS network

sextrans · abstract · 2026-05-20 · 1 matching annotations

87.3%

bictegravir raltegravir/elvitegravir-based dolutegravir-based protease inhibitor-based PWH Italian NGS Network

…-RNA was 3.9 (IQR: 3.0–4.8) log10 copies/mL. PWH were receiving bictegravir/dolutegravir-based (37.0%), raltegravir/elvitegravir-based (22.…

P32 Long-term renal outcomes after switch to bictegravir: determinants of clinically significant decline at week 144 in the BICTEL cohort

sextrans · abstract · 2026-05-20 · 1 matching annotations

88.4%

bictegravir emtricitabine tenofovir alafenamide diabetes Gilead Sciences Medical grant HIV hypertension

…Background Long-term real-world data on bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) remain limite…

SC35 Drivers of B/F/TAF discontinuation: reflecting strategy rather than failure or toxicity

sextrans · abstract · 2026-05-20 · 1 matching annotations

89.7%

B/F/TAF Bictegravir tenofovir alafenamide emtricitabine HIV PWH

…o or initiating their first antiretroviral treatment (ART) with B/F/TAF were included. PWH were followed up until treatment discontinua…

Evolution and forecasting of antiretroviral therapy utilisation in British Columbia: a population-level analysis of provincial drug treatment programme data, 2014–2024

bmjopen · abstract · 2026-04-29 · 1 matching annotations

88.0%

dolutegravir bictegravir emtricitabine tenofovir alafenamide bictegravir-containing HIV

… strand transfer inhibitor (INSTI)-based regimens, particularly dolutegravir- and bictegravir-containing combinations, increased steadily, w…

Single high-dose liposomal amphotericin B plus B/F/TAF for AIDS-associated talaromycosis in China: a multicentre randomised controlled trial protocol

bmjopen · abstract · 2025-11-19 · 1 matching annotations

83.5%

AmBD itraconazole capsule emtricitabine bictegravir tenofovir alafenamide fumarate L-AMB amphotericin B Talaromycosis Mengchao Hepatobiliary Hospital of Fujian Medical University Guiyang Public Health Treatment Centre+2 more

…12 hours for the remaining 13 days of induction therapy, versus AmBD (0.5 mg/kg/day for 14 days) as induction therapy for AIDS-assoc…